Furthermore, the combination of PI3K and CDK4/6 inhibitors was shown to overcome intrinsic and adaptive PI3K inhibitor resistance, causing regressions in PIK3CA mutant tumour xenograft models. This evidence concerns the gene PIK3CD and neoplasm.